Bladder Cancer Clinical Trial

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Summary

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.

View Full Description

Full Description

This Phase 1/2 study consists of two parts: Phase 1 Dose Escalation and Phase 2 Dose Expansion. In Phase 1 Dose Escalation, STAR0602 will be administered intravenously in participants with advanced solid tumors to assess safety/tolerability profile of STAR0602 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of STAR0602. In Phase 2 Dose Expansion, STAR0602 at RP2D will be administered to participants with advanced, antigen-rich solid tumors to further evaluate safety and assess preliminary clinical activity of STAR0602. Clinical activity will be evaluated by objective tumor response rate (ORR), duration of response (DOR), disease control rate (DCR), and progression free survival (PFS).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants must have histologically confirmed solid tumors that are unresectable, locally advanced, or metastatic and for which standard curative therapies do not exist or are no longer effective.

For Phase 1, participants must have one of the following solid tumors:

High mutational burden (TMB-H)
Microsatellite Instability (MSI-H)/DNA mismatch repair (dMMR)
Virally associated tumors

For Phase 2, participants must have one of the following solid tumors:

TMB-H
MSI-H/dMMR
Virally associated tumors
Metastatic triple negative breast cancer
Relapsed and refractory epithelial ovarian cancer
Metastatic castration-resistance prostate cancer
K-Ras wild type colorectal cancer (CRC)
K-Ras mutant CRC
Primary stage IV or recurrent non-small cell lung cancer

(Other tumor histologies may also be included in Phase 2 as additional data emerge to support their inclusion.)

Symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic for ≥ 14 days, and meet the following at the time of enrollment:

No concurrent treatment for CNS disease (e.g., surgery, radiation, corticosteroids > 10 mg prednisone/day or equivalent);
No concurrent leptomeningeal disease or cord compression.

Exclusion Criteria:

Participants with a history of known autoimmune disease with exceptions of:

Vitiligo;
Psoriasis, atopic dermatitis or other autoimmune skin condition not requiring systemic treatment;
History of Graves' disease, now euthyroid for > 4 weeks;
Hypothyroidism managed by thyroid replacement;
Alopecia;
Arthritis managed without systemic therapy beyond oral nonsteroidal anti-inflammatory drugs.
Adrenal insufficiency well controlled on replacement therapy.
Major surgery or traumatic injury within 8 weeks before first dose of study drug.
Unhealed wounds from surgery or injury.
Treatment with >10 mg per day of prednisone (or equivalent) or other immune-suppressive drugs within 7 days prior to the initiation of study drug. Exceptions may be made for patients who have had allergic reaction to iodinated contrast media. Steroids for topical, ophthalmic, inhaled, or nasal administration are allowed.
Clinically significant cardiovascular/vascular disease, gastrointestinal disorders, inflammatory processes, pulmonary compromises
Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug.
Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.
Participants who are known to be human immunodeficiency virus positive or hepatitis B or C positive and have uncontrolled disease.
Second primary invasive malignancy not in remission for ≥ 1 year. Exceptions include non-melanoma locally advanced skin cancer, cervical carcinoma in situ, localized prostate cancer (Gleason score ≤ 7), resected melanoma in situ, or any malignancy considered to be indolent and never required systemic therapy, with the exception of indolent lymphomas.
Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation).

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

365

Study ID:

NCT05592626

Recruitment Status:

Recruiting

Sponsor:

Marengo Therapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

AdventHealth Celebration
Celebration Florida, 34747, United States More Info
Guru Sonpavde, MD
Contact
407-303-2024
Guru Sonpavde, MD
Principal Investigator
University of Miami Sylvester Comprehensive Cancer Center
Miami Florida, 33136, United States More Info
Marijo Billusic, MD
Contact
307-243-1543
Marijo Billusic, MD
Principal Investigator
National Institutes of Health
Bethesda Maryland, 20892, United States More Info
Erica Redmond
Contact
240-858-3783
James Gulley, MD, PhD
Principal Investigator
Massachusetts General Hospital Cancer Center
Boston Massachusetts, 02114, United States More Info
Ryan Sullivan, MD
Contact
617-643-3614
Ryan Sullivan, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
New York New York, 10065, United States More Info
Claire Friedman, MD
Contact
646-888-4247
Claire Friedman, MD
Principal Investigator
The Ohio State University Comprehensive Cancer Center
Columbus Ohio, 43210, United States More Info
Kai He, MD
Contact
614-366-4139
Kai He, MD
Principal Investigator
Princess Margaret Cancer Centre
Toronto Ontario, M5G 2, Canada More Info
Lillian Siu, MD
Contact
416-946-2911
Lillian Siu, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

365

Study ID:

NCT05592626

Recruitment Status:

Recruiting

Sponsor:


Marengo Therapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.